20:04 , Apr 25, 2019 |  BC Innovations  |  Finance

The academic founders' conundrum

First-time academic entrepreneurs face a circular problem: while they’re continually sought after by VCs and pharmas seeking the next “big thing”, they also face an arduous path to establish their bona fides - not for...
11:09 , Apr 16, 2019 |  BioCentury  |  Emerging Company Profile

Kintai’s host-targeting niche in Flagship microbiome ecosystem

Kintai, Flagship’s latest foray into microbiome-based medicines, is taking bugs out of the equation by developing oral small molecules that mimic microbes’ therapeutic effects. Emerging from stealth mode Tuesday and led by Paul-Peter Tak as...
02:31 , Mar 15, 2019 |  BC Innovations  |  Product Development

The microbiome universe in two maps

In its “big bang” over the last decade, the universe of microbiome therapeutics has expanded far beyond its origins of fecal transplants, used primarily for C. difficile . Mapping biotech activity reveals a broadening range...
19:37 , Apr 20, 2018 |  Completed Offerings  |  Completed Offerings

Tmunity adds $35M to series A round

T cell immunotherapy company Tmunity Therapeutics Inc. (Philadelphia, Pa.) raised an additional $35 million for its series A round from Kleiner Perkins and affiliates, bringing the round's total to $135 million. In January, the company...
11:08 , Apr 19, 2018 |  BC Extra  |  Financial News

Tmunity tops off series A round

T cell immunotherapy company Tmunity Therapeutics Inc. (Philadelphia, Pa.) raised an additional $35 million for its series A round from Kleiner Perkins and affiliates, bringing the round's total to $135 million. In January, the company...
13:43 , Apr 13, 2018 |  BC Week In Review  |  Financial News

Magenta Therapeutics raises $52M series C

Stem cell therapy company Magenta Therapeutics Inc. (Cambridge, Mass.) raised $52 million on April 9 in an untranched, oversubscribed series C round led by Casdin Capital. New investors EcoR1 Capital, Eventide and Watermill were joined...
23:20 , Apr 9, 2018 |  BC Extra  |  Financial News

Magenta Therapeutics raises $52M series C

Magenta Therapeutics Inc. (Cambridge, Mass.) raised $52 million in an untranched, oversubscribed series C round led by Casdin Capital. New investors EcoR1 Capital, Eventide and Watermill were joined by existing investors Be the Match BioTherapies...
18:54 , Mar 23, 2018 |  BC Week In Review  |  Company News

Harvard licenses reglemer IP to Symbiotix

Harvard Medical School granted Symbiotix Biotherapies Inc. (Boston, Mass.) exclusive rights to IP related to the glycolipid component of polysaccharide A, which is the basis of Symbiotix lead candidate SYMB-104. The IP was developed in...
23:24 , Jan 26, 2018 |  BioCentury  |  Finance

Tmunity’s A team

An all-star team with a proven track record in cell therapy enabled Tmunity Therapeutics Inc. to raise a $100 million series A round that included opportunistic investments from non-profits Be the Match BioTherapies and Parker...
17:09 , Jan 26, 2018 |  BC Week In Review  |  Financial News

Tmunity raises $100M series A

T cell immunotherapy company Tmunity Therapeutics Inc. (Philadelphia, Pa.) raised $100 million in a series A round Tuesday from new investors Ping An Ventures, Parker Institute for Cancer Immunotherapy, Gilead Sciences Inc. (NASDAQ:GILD) and Be...